Безопасность и риск фармакотерапии
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
About the journal
Безопасность и риск фармакотерапии is an open-access journal published by Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» in Russia, publishing in russian. It is listed in DOAJ according to the sources read. Declared review time at DOAJ: 12 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
- ISSN
- 2312-7821 · 2619-1164
- Country
- Russia
- Languages
- russian
- Access
- Open access
- Articles in DOAJ
- 401
- Declared review time
- 12 weeks
- Declared peer-review model
- double_blind
- Official website
- https://www.risksafety.ru/
Index listings
- DOAJ · 2018-10-25
- Indexing
- DOAJ
- APC
- —
- Declared review time (DOAJ)
- 12 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
401
Most recent article
2 months ago
Average review time (journal-declared via DOAJ)
12weeks
Works in OpenAlex
367
Last recorded publication year
2025
h-index
9
i10-index
9
From OpenAlex open data (CC0).
Editorial & policy8
- Last DOAJ review date
- 2023-02-23
- Added to DOAJ
- 2018-10-25
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Editorial board
- Official page ↗
- Open references deposited at Crossref
- 85%
- ORCID iDs in current deposits
- 88%
- Deposits licence metadata at Crossref
- ✓
- Peer-review policy
- View policy
Identity & continuity2
- Alternate titles
- Safety and risk of pharmacotherapy
- Source type
- journal
Classification2
Subjects (DOAJ)
LCC codes
Subject areas
- Pharmacovigilance and Adverse Drug Reactions
- Pharmacovigilance and Adverse Drug Reactions
- Military Technology and Strategies
- Linguistic, Cultural, and Literary Studies
- Legal and Regulatory Analysis
- Linguistic, Cultural, and Literary Studies
- Computational Drug Discovery Methods
- Computational Drug Discovery Methods
Show all subjects (50)
- Military Technology and Strategies
- Legal and Regulatory Analysis
- Pharmaceutical studies and practices
- Pharmaceutical studies and practices
- Pharmaceutical Economics and Policy
- Pharmaceutical Economics and Policy
- Drug-Induced Hepatotoxicity and Protection
- Drug-Induced Hepatotoxicity and Protection
- Drug-Induced Adverse Reactions
- Academic Publishing and Open Access
- Academic Publishing and Open Access
- Drug-Induced Adverse Reactions
- Pharmaceutical Quality and Counterfeiting
- Pharmaceutical Quality and Counterfeiting
- Healthcare Systems and Public Health
- Healthcare Systems and Public Health
- Pharmaceutical Practices and Patient Outcomes
- Pharmacological Effects and Toxicity Studies
- SARS-CoV-2 and COVID-19 Research
- Pharmacological Effects and Toxicity Studies
- Pharmaceutical Practices and Patient Outcomes
- SARS-CoV-2 and COVID-19 Research
- Pharmacogenetics and Drug Metabolism
- Pharmacogenetics and Drug Metabolism
- Biosimilars and Bioanalytical Methods
- Biosimilars and Bioanalytical Methods
- Academic integrity and plagiarism
- Lipoproteins and Cardiovascular Health
- Lipoproteins and Cardiovascular Health
- Academic integrity and plagiarism
- Pharmacy and Medical Practices
- Antibiotic Use and Resistance
- Antibiotic Use and Resistance
- Pharmacy and Medical Practices
- COVID-19 Clinical Research Studies
- COVID-19 Clinical Research Studies
- Schizophrenia research and treatment
- Inflammatory mediators and NSAID effects
- Inflammatory mediators and NSAID effects
- Antimicrobial Resistance in Staphylococcus
- Schizophrenia research and treatment
- Antimicrobial Resistance in Staphylococcus
Keywords (DOAJ)
- drug safety
- undesirable side reactions
- signals
- risks of pharmacotherapy
- pharmacovigilance
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ